Occidental Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.66M | Sell |
10,577
-490
| -4% | -$105K | 0.26% | 84 |
|
|
2026
Q1 | $2.41M | Buy |
11,067
+540
| +5% | +$120K | 0.29% | 82 |
|
|
2025
Q4 | $2.41M | Buy |
10,527
+983
| +10% | +$224K | 0.29% | 79 |
|
|
2025
Q3 | $2.21M | Buy |
9,544
+1,485
| +18% | +$302K | 0.28% | 81 |
|
|
2025
Q2 | $1.5M | Buy |
8,059
+105
| +1% | +$19.5K | 0.21% | 87 |
|
|
2025
Q1 | $1.67M | Buy |
7,954
+611
| +8% | +$119K | 0.25% | 85 |
|
|
2024
Q4 | $1.3M | Sell |
7,343
-647
| -8% | -$119K | 0.2% | 95 |
|
|
2024
Q3 | $1.58M | Buy |
7,990
+537
| +7% | +$100K | 0.25% | 93 |
|
|
2024
Q2 | $1.28M | Buy |
7,453
+117
| +2% | +$19.4K | 0.22% | 99 |
|
|
2024
Q1 | $1.34M | Buy |
7,336
+927
| +14% | +$160K | 0.25% | 94 |
|
|
2023
Q4 | $993K | Sell |
6,409
-87
| -1% | -$12.7K | 0.21% | 113 |
|
|
2023
Q3 | $968K | Buy |
6,496
+38
| +0.6% | +$5.58K | 0.22% | 107 |
|
|
2023
Q2 | $870K | Buy |
6,458
+137
| +2% | +$20.1K | 0.2% | 116 |
|
|
2023
Q1 | $1.01M | Sell |
6,321
-47
| -0.7% | -$7.19K | 0.25% | 105 |
|
|
2022
Q4 | $1.03M | Buy |
6,368
+2,508
| +65% | +$385K | 0.28% | 102 |
|
|
2022
Q3 | $518K | Buy |
3,860
+125
| +3% | +$17.9K | 0.16% | 120 |
|
|
2022
Q2 | $572K | Buy |
3,735
+135
| +4% | +$20.6K | 0.17% | 115 |
|
|
2022
Q1 | $584K | Buy |
3,600
+100
| +3% | +$14.5K | 0.15% | 121 |
|
|
2021
Q4 | $474K | Hold |
3,500
| – | – | 0.11% | 144 |
|
|
2021
Q3 | $378K | Hold |
3,500
| – | – | 0.1% | 159 |
|
|
2021
Q2 | $394K | Hold |
3,500
| – | – | 0.1% | 156 |
|
|
2021
Q1 | $379K | Sell |
3,500
-11,607
| -77% | -$1.24M | 0.11% | 148 |
|
|
2020
Q4 | $1.62M | Buy |
15,107
+750
| +5% | +$72.1K | 0.54% | 36 |
|
|
2020
Q3 | $1.26M | Buy |
14,357
+52
| +0.4% | +$4.9K | 0.52% | 41 |
|
|
2020
Q2 | $1.4M | Buy |
14,305
+1,288
| +10% | +$113K | 0.62% | 29 |
|
|
2020
Q1 | $992K | Buy |
13,017
+1,978
| +18% | +$168K | 0.5% | 42 |
|
|
2019
Q4 | $977K | Buy |
11,039
+793
| +8% | +$65.8K | 0.4% | 60 |
|
|
2019
Q3 | $776K | Buy |
10,246
+2,581
| +34% | +$177K | 0.33% | 76 |
|
|
2019
Q2 | $557K | Buy |
7,665
+1,231
| +19% | +$96.8K | 0.25% | 89 |
|
|
2019
Q1 | $519K | Buy |
+6,434
| New | +$526K | 0.25% | 84 |
|
|
2018
Q2 | – | Sell |
-2,400
| Closed | -$227K | – | 150 |
|
|
2018
Q1 | $227K | Hold |
2,400
| – | – | 0.12% | 133 |
|
|
2017
Q4 | $232K | Hold |
2,400
| – | – | 0.12% | 131 |
|
|
2017
Q3 | $213K | Buy |
+2,400
| New | +$183K | 0.12% | 128 |
|
Other funds holding ABBV
Occidental Asset Management's ABBV Position: Q2 2026 in Review
Occidental Asset Management reduced its AbbVie (ABBV) stake by 4.4% in Q2 2026, selling an estimated $105K and leaving 10,577 shares worth $2.66M. The position accounts for 0.26% of the portfolio, ranked #84.
Occidental Asset Management first reported a position in ABBV in Q3 2017 and has held it in 33 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Occidental Asset Management held 10,577 shares of AbbVie worth $2.66M as of Q2 2026.
- Occidental Asset Management sold 490 AbbVie shares in Q2 2026, an estimated $105K.
- AbbVie made up 0.26% of Occidental Asset Management's portfolio in Q2 2026, its #84 holding.
- Occidental Asset Management first reported a position in AbbVie in Q3 2017 and has held it in 33 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Occidental Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.